{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:51:46Z","timestamp":1793400706118,"version":"4.5.0"},"reference-count":124,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T00:00:00Z","timestamp":1779494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12012-026-10130-x","type":"journal-article","created":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T14:54:14Z","timestamp":1779548054000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["QT Prolongation and Arrhythmias in Cancer Therapy: A Narrative Review of Mechanistic and Clinical Studies"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4004-9290","authenticated-orcid":false,"given":"Kayode E.","family":"Ogunniyi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2287-5727","authenticated-orcid":false,"given":"Trie Arni","family":"Djunadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5722-0618","authenticated-orcid":false,"given":"Samuel Abiola","family":"Ayedun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-9898","authenticated-orcid":false,"given":"Victor","family":"Onyenokwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-3098","authenticated-orcid":false,"given":"Oghenevwede Anderson","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1601-5118","authenticated-orcid":false,"given":"Eric","family":"Sanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-8506-1890","authenticated-orcid":false,"given":"Andrew","family":"Greek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,23]]},"reference":[{"issue":"9","key":"10130_CR1","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1016\/S1470-2045(22)00221-2","volume":"23","author":"EL Giraud","year":"2022","unstructured":"Giraud, E. L., Ferrier, K. R. M., Lankheet, N. A. G., et al. (2022). The QT interval prolongation potential of anticancer and supportive drugs: a comprehensive overview. The Lancet Oncology, 23(9), e406\u2013e415. https:\/\/doi.org\/10.1016\/S1470-2045(22)00221-2","journal-title":"The Lancet Oncology"},{"issue":"11","key":"10130_CR2","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jacc.2008.12.016","volume":"53","author":"GS Wagner","year":"2009","unstructured":"Wagner, G. S., Macfarlane, P., Wellens, H., et al. (2009). AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia\/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society. Endorsed by the International Society for Computerized Electrocardiology. Journal Of The American College Of Cardiology, 53(11), 1003\u20131011. https:\/\/doi.org\/10.1016\/j.jacc.2008.12.016","journal-title":"Journal Of The American College Of Cardiology"},{"issue":"14","key":"10130_CR3","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.1016\/j.jacc.2017.10.054","volume":"72","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib, S. M., Stevenson, W. G., Ackerman, M. J., et al. (2018). 2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal Of The American College Of Cardiology, 72(14), e91\u2013e220. https:\/\/doi.org\/10.1016\/j.jacc.2017.10.054","journal-title":"Journal Of The American College Of Cardiology"},{"issue":"9974","key":"10130_CR4","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1016\/S0140-6736(14)61396-9","volume":"385","author":"M Quaresma","year":"2015","unstructured":"Quaresma, M., Coleman, M. P., & Rachet, B. (2015). 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971\u20132011: a population-based study. Lancet, 385(9974), 1206\u20131218. https:\/\/doi.org\/10.1016\/S0140-6736(14)61396-9","journal-title":"Lancet"},{"issue":"22","key":"10130_CR5","doi-asserted-by":"publisher","first-page":"16261","DOI":"10.3390\/ijms242216261","volume":"24","author":"K Furutani","year":"2023","unstructured":"Furutani, K. (2023). Facilitation of hERG activation by its blocker: A mechanism to reduce drug-induced proarrhythmic risk. International Journal Of Molecular Sciences, 24(22), 16261. https:\/\/doi.org\/10.3390\/ijms242216261","journal-title":"International Journal Of Molecular Sciences"},{"issue":"10","key":"10130_CR6","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s11912-023-01445-x","volume":"25","author":"M Gawlik","year":"2023","unstructured":"Gawlik, M., Zimodro, J. M., G\u0105secka, A., Filipiak, K. J., & Szmit, S. (2023). Cardiac arrhythmias in oncological patients-epidemiology, risk factors, and management within the context of the new ESC 2022 guidelines. Current Oncology Reports, 25(10), 1107\u20131115. https:\/\/doi.org\/10.1007\/s11912-023-01445-x","journal-title":"Current Oncology Reports"},{"issue":"7083","key":"10130_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature04710","volume":"440","author":"MC Sanguinetti","year":"2006","unstructured":"Sanguinetti, M. C., & Tristani-Firouzi, M. (2006). hERG potassium channels and cardiac arrhythmia. Nature, 440(7083), 463\u2013469. https:\/\/doi.org\/10.1038\/nature04710","journal-title":"Nature"},{"issue":"12","key":"10130_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/JAHA.117.007724","volume":"6","author":"A Porta-S\u00e1nchez","year":"2017","unstructured":"Porta-S\u00e1nchez, A., Gilbert, C., Spears, D., et al. (2017). Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: A systematic review. Journal of the American Heart Association, 6(12), 1\u201318. https:\/\/doi.org\/10.1161\/JAHA.117.007724","journal-title":"Journal of the American Heart Association"},{"issue":"41","key":"10130_CR9","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"Lyon, A. R., L\u00f3pez-Fern\u00e1ndez, T., Couch, L. S., et al. (2022). 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European Heart Journal, 43(41), 4229\u20134361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244","journal-title":"European Heart Journal"},{"issue":"2","key":"10130_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.pcad.2010.05.005","volume":"53","author":"JM Brell","year":"2010","unstructured":"Brell, J. M. (2010). Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy. Progress In Cardiovascular Diseases, 53(2), 164\u2013172. https:\/\/doi.org\/10.1016\/j.pcad.2010.05.005","journal-title":"Progress In Cardiovascular Diseases"},{"issue":"36","key":"10130_CR11","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","volume":"37","author":"JL Zamorano","year":"2016","unstructured":"Zamorano, J. L., Lancellotti, P., Rodriguez Mu\u00f1oz, D., et al. (2016). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal, 37(36), 2768\u20132801. https:\/\/doi.org\/10.1093\/eurheartj\/ehw211","journal-title":"European Heart Journal"},{"key":"10130_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.pharmthera.2018.04.009","volume":"189","author":"J Alexandre","year":"2018","unstructured":"Alexandre, J., Moslehi, J. J., Bersell, K. R., Funck-Brentano, C., Roden, D. M., & Salem, J. E. (2018). Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. Pharmacology & Therapeutics, 189, 89\u2013103. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.04.009","journal-title":"Pharmacology & Therapeutics"},{"issue":"33","key":"10130_CR13","doi-asserted-by":"publisher","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","volume":"32","author":"GJ Roboz","year":"2014","unstructured":"Roboz, G. J., Ritchie, E. K., Carlin, R. F., et al. (2014). Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide. Journal Of Clinical Oncology, 32(33), 3723\u20133728. https:\/\/doi.org\/10.1200\/JCO.2013.51.2913","journal-title":"Journal Of Clinical Oncology"},{"issue":"19","key":"10130_CR14","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1200\/JCO.2003.10.009","volume":"21","author":"JT Barbey","year":"2003","unstructured":"Barbey, J. T., Pezzullo, J. C., & Soignet, S. L. (2003). Effect of arsenic trioxide on QT interval in patients with advanced malignancies. Journal Of Clinical Oncology, 21(19), 3609\u20133615. https:\/\/doi.org\/10.1200\/JCO.2003.10.009","journal-title":"Journal Of Clinical Oncology"},{"issue":"1","key":"10130_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/01.CIR.0000109484.00668.CE","volume":"109","author":"B Drolet","year":"2004","unstructured":"Drolet, B., Simard, C., & Roden, D. M. (2004). Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation, 109(1), 26\u201329. https:\/\/doi.org\/10.1161\/01.CIR.0000109484.00668.CE","journal-title":"Circulation"},{"issue":"2","key":"10130_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40264-014-0258-4","volume":"38","author":"J Tamargo","year":"2015","unstructured":"Tamargo, J., Caballero, R., & Delp\u00f3n, E. (2015). Cancer chemotherapy and cardiac arrhythmias: a review. Drug Safety, 38(2), 129\u2013152. https:\/\/doi.org\/10.1007\/s40264-014-0258-4","journal-title":"Drug Safety"},{"issue":"2","key":"10130_CR17","first-page":"115","volume":"31","author":"JM Horacek","year":"2009","unstructured":"Horacek, J. M., Jakl, M., Horackova, J., Pudil, R., Jebavy, L., & Maly, J. (2009). Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Experimental Oncology, 31(2), 115\u2013117.","journal-title":"Experimental Oncology"},{"issue":"8","key":"10130_CR18","doi-asserted-by":"publisher","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","volume":"10","author":"V Buza","year":"2017","unstructured":"Buza, V., Rajagopalan, B., & Curtis, A. B. (2017). Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies. Circ Arrhythm Electrophysiol, 10(8), e005443. https:\/\/doi.org\/10.1161\/CIRCEP.117.005443","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"4","key":"10130_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1124\/mol.114.093849","volume":"86","author":"AD Hanna","year":"2014","unstructured":"Hanna, A. D., Lam, A., Tham, S., Dulhunty, A. F., & Beard, N. A. (2014). Adverse effects of doxorubicin and its metabolic product on cardiac RyR2 and SERCA2A. Molecular Pharmacology, 86(4), 438\u2013449. https:\/\/doi.org\/10.1124\/mol.114.093849","journal-title":"Molecular Pharmacology"},{"issue":"1","key":"10130_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.res.86.1.8","volume":"86","author":"M Arai","year":"2000","unstructured":"Arai, M., Yoguchi, A., Takizawa, T., et al. (2000). Mechanism of doxorubicin-induced inhibition of sarcoplasmic reticulum Ca(2+)-ATPase gene transcription. Circ Res, 86(1), 8\u201314. https:\/\/doi.org\/10.1161\/01.res.86.1.8","journal-title":"Circ Res"},{"issue":"1","key":"10130_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/j.1476-5381.2009.00371.x","volume":"159","author":"J Ducroq","year":"2010","unstructured":"Ducroq, J., Moha ou Maati, H., Guilbot, S., et al. (2010). Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks). British Journal Of Pharmacology, 159(1), 93\u2013101. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00371.x","journal-title":"British Journal Of Pharmacology"},{"issue":"3","key":"10130_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/s0008-6363(98)00034-0","volume":"38","author":"P Venditti","year":"1998","unstructured":"Venditti, P., Balestrieri, M., De Leo, T., & Di Meo, S. (1998). Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res, 38(3), 695\u2013702. https:\/\/doi.org\/10.1016\/s0008-6363(98)00034-0","journal-title":"Cardiovasc Res"},{"issue":"18","key":"10130_CR23","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1161\/01.CIR.0000146889.46519.27","volume":"110","author":"N Nozaki","year":"2004","unstructured":"Nozaki, N., Shishido, T., Takeishi, Y., & Kubota, I. (2004). Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation, 110(18), 2869\u20132874. https:\/\/doi.org\/10.1161\/01.CIR.0000146889.46519.27","journal-title":"Circulation"},{"issue":"4","key":"10130_CR24","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.yjmcc.2010.11.003","volume":"51","author":"VK Topkara","year":"2011","unstructured":"Topkara, V. K., Evans, S., Zhang, W., et al. (2011). Therapeutic targeting of innate immunity in the failing heart. Journal Of Molecular And Cellular Cardiology, 51(4), 594\u2013599. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.11.003","journal-title":"Journal Of Molecular And Cellular Cardiology"},{"issue":"5","key":"10130_CR25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","volume":"80","author":"B Oronsky","year":"2017","unstructured":"Oronsky, B., Caroen, S., Oronsky, A., et al. (2017). Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management. Cancer Chemotherapy And Pharmacology, 80(5), 895\u2013907. https:\/\/doi.org\/10.1007\/s00280-017-3392-8","journal-title":"Cancer Chemotherapy And Pharmacology"},{"key":"10130_CR26","unstructured":"184-Prevention and management of cisplatin induced nephrotoxicity | eviQ. Accessed March 4 (2026). https:\/\/www.eviq.org.au\/clinical-resources\/side-effect-and-toxicity-management\/prophylaxis-and-treatment\/184-prevention-and-management-of-cisplatin-induced?utm_source=chatgpt.com"},{"issue":"5 Suppl 12","key":"10130_CR27","first-page":"88","volume":"22","author":"DS Alberts","year":"1995","unstructured":"Alberts, D. S. (1995). Carboplatin versus cisplatin in ovarian cancer. Seminars In Oncology, 22(5 Suppl 12), 88\u201390.","journal-title":"Seminars In Oncology"},{"issue":"5","key":"10130_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40264-013-0047-5","volume":"36","author":"RR Shah","year":"2013","unstructured":"Shah, R. R., Morganroth, J., & Shah, D. R. (2013). Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Safety, 36(5), 295\u2013316. https:\/\/doi.org\/10.1007\/s40264-013-0047-5","journal-title":"Drug Safety"},{"issue":"3","key":"10130_CR29","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1124\/jpet.105.093393","volume":"316","author":"AN Katchman","year":"2006","unstructured":"Katchman, A. N., Koerner, J., Tosaka, T., Woosley, R. L., & Ebert, S. N. (2006). Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. Journal Of Pharmacology And Experimental Therapeutics, 316(3), 1098\u20131106. https:\/\/doi.org\/10.1124\/jpet.105.093393","journal-title":"Journal Of Pharmacology And Experimental Therapeutics"},{"issue":"8","key":"10130_CR30","doi-asserted-by":"publisher","first-page":"e0181875","DOI":"10.1371\/journal.pone.0181875","volume":"12","author":"JE Salem","year":"2017","unstructured":"Salem, J. E., Germain, M., Hulot, J. S., et al. (2017). GENomE wide analysis of sotalol-induced IKr inhibition during ventricular REPOLarization, GENEREPOL study: Lack of common variants with large effect sizes. PLoS One, 12(8), e0181875. https:\/\/doi.org\/10.1371\/journal.pone.0181875","journal-title":"PLoS One"},{"issue":"10","key":"10130_CR31","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden, D. M. (2004). Drug-induced prolongation of the QT interval. New England Journal Of Medicine, 350(10), 1013\u20131022. https:\/\/doi.org\/10.1056\/NEJMra032426","journal-title":"New England Journal Of Medicine"},{"issue":"3","key":"10130_CR32","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1161\/CIRCULATIONAHA.113.007765","volume":"130","author":"T Yang","year":"2014","unstructured":"Yang, T., Chun, Y. W., Stroud, D. M., et al. (2014). Screening for acute IKr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation, 130(3), 224\u2013234. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.007765","journal-title":"Circulation"},{"issue":"39","key":"10130_CR33","doi-asserted-by":"publisher","first-page":"27457","DOI":"10.1074\/jbc.274.39.27457","volume":"274","author":"D Thomas","year":"1999","unstructured":"Thomas, D., Zhang, W., Karle, C. A., et al. (1999). Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. Journal Of Biological Chemistry, 274(39), 27457\u201327462. https:\/\/doi.org\/10.1074\/jbc.274.39.27457","journal-title":"Journal Of Biological Chemistry"},{"issue":"131","key":"10130_CR34","doi-asserted-by":"publisher","first-page":"131ra50","DOI":"10.1126\/scitranslmed.3003623","volume":"4","author":"Z Lu","year":"2012","unstructured":"Lu, Z., Wu, C. Y. C., Jiang, Y. P., et al. (2012). Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome. Science Translational Medicine, 4(131), 131ra50. https:\/\/doi.org\/10.1126\/scitranslmed.3003623","journal-title":"Science Translational Medicine"},{"issue":"11","key":"10130_CR35","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1002\/ijc.33119","volume":"147","author":"AA Abu Rmilah","year":"2020","unstructured":"Abu Rmilah, A. A., Lin, G., Begna, K. H., Friedman, P. A., & Herrmann, J. (2020). Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors. International Journal Of Cancer, 147(11), 3160\u20133167. https:\/\/doi.org\/10.1002\/ijc.33119","journal-title":"International Journal Of Cancer"},{"issue":"1","key":"10130_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023). Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther, 8(1), 262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10130_CR37","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"Wells, S. A., Robinson, B. G., Gagel, R. F., et al. (2012). Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. Journal Of Clinical Oncology, 30(2), 134\u2013141. https:\/\/doi.org\/10.1200\/JCO.2011.35.5040","journal-title":"Journal Of Clinical Oncology"},{"issue":"9","key":"10130_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s40265-018-0916-4","volume":"78","author":"A D\u00edaz-Serrano","year":"2018","unstructured":"D\u00edaz-Serrano, A., Gella, P., Jim\u00e9nez, E., Zugazagoitia, J., & Paz-Ares Rodr\u00edguez, L. (2018). Targeting EGFR in Lung Cancer: Current Standards and Developments. Drugs, 78(9), 893\u2013911. https:\/\/doi.org\/10.1007\/s40265-018-0916-4","journal-title":"Drugs"},{"issue":"9","key":"10130_CR39","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters, S., Camidge, D. R., Shaw, A. T., et al. (2017). Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. New England Journal Of Medicine, 377(9), 829\u2013838. https:\/\/doi.org\/10.1056\/NEJMoa1704795","journal-title":"New England Journal Of Medicine"},{"issue":"12","key":"10130_CR40","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","volume":"19","author":"BJ Solomon","year":"2018","unstructured":"Solomon, B. J., Besse, B., Bauer, T. M., et al. (2018). Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. The Lancet Oncology, 19(12), 1654\u20131667. https:\/\/doi.org\/10.1016\/S1470-2045(18)30649-1","journal-title":"The Lancet Oncology"},{"issue":"21","key":"10130_CR41","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1016\/j.jacc.2021.04.009","volume":"77","author":"VU Rao","year":"2021","unstructured":"Rao, V. U., Reeves, D. J., Chugh, A. R., et al. (2021). Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. Journal Of The American College Of Cardiology, 77(21), 2693\u20132716. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.009","journal-title":"Journal Of The American College Of Cardiology"},{"key":"10130_CR42","unstructured":"Home (2025). :: Crediblemeds. Accessed September 21. https:\/\/crediblemeds.org\/"},{"issue":"11","key":"10130_CR43","doi-asserted-by":"publisher","first-page":"e70065","DOI":"10.1111\/cts.70065","volume":"17","author":"P Vaddady","year":"2024","unstructured":"Vaddady, P., Smania, G., Nakayama, S., et al. (2024). Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia. Clinical And Translational Science, 17(11), e70065. https:\/\/doi.org\/10.1111\/cts.70065","journal-title":"Clinical And Translational Science"},{"key":"10130_CR44","doi-asserted-by":"publisher","unstructured":"Miyazaki, Y., Matsumura, I., Arita, T., Fukuda, R., & Yamanaka, M. (2026). Post-marketing surveillance of quizartinib for relapsed or refractory FLT3-ITD-positive acute myeloid leukemia in Japan. Int J Hematol Published online February, 26. https:\/\/doi.org\/10.1007\/s12185-026-04181-7","DOI":"10.1007\/s12185-026-04181-7"},{"issue":"13","key":"10130_CR45","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","volume":"27","author":"ED Pulte","year":"2021","unstructured":"Pulte, E. D., Norsworthy, K. J., Wang, Y., et al. (2021). FDA Approval Summary: Gilteritinib for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Clinical Cancer Research, 27(13), 3515\u20133521. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4271","journal-title":"Clinical Cancer Research"},{"issue":"8","key":"10130_CR46","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-20-3558","volume":"27","author":"D Bradford","year":"2021","unstructured":"Bradford, D., Larkins, E., Mushti, S. L., et al. (2021). FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions. Clinical Cancer Research, 27(8), 2130\u20132135. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3558","journal-title":"Clinical Cancer Research"},{"key":"10130_CR47","doi-asserted-by":"publisher","first-page":"1424980","DOI":"10.3389\/fphar.2024.1424980","volume":"15","author":"Q Jie","year":"2024","unstructured":"Jie, Q., Li, Y., Jing, L., Chen, J., & Li, Y. (2024). Adverse event profile differences between pralsetinib and selpercatinib: a real-world study based on the FDA adverse events reporting system. Frontiers In Pharmacology, 15, 1424980. https:\/\/doi.org\/10.3389\/fphar.2024.1424980","journal-title":"Frontiers In Pharmacology"},{"issue":"12","key":"10130_CR48","doi-asserted-by":"publisher","first-page":"101332","DOI":"10.1016\/j.xcrm.2023.101332","volume":"4","author":"M Nardo","year":"2023","unstructured":"Nardo, M., Gouda, M. A., Nelson, B. E., et al. (2023). Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers. Cell Rep Med, 4(12), 101332. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101332","journal-title":"Cell Rep Med"},{"key":"10130_CR49","doi-asserted-by":"publisher","unstructured":"Frampton, J. E., & Entrectinib (2021). A Review in NTRK+ Solid Tumours and ROS1 + NSCLC. Drugs, 81(6), 697\u2013708. https:\/\/doi.org\/10.1007\/s40265-021-01503-3","DOI":"10.1007\/s40265-021-01503-3"},{"issue":"18","key":"10130_CR50","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-20-1630","volume":"26","author":"KP Papadopoulos","year":"2020","unstructured":"Papadopoulos, K. P., Borazanci, E., Shaw, A. T., et al. (2020). U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b\/AB-106), a ROS1\/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clinical Cancer Research, 26(18), 4785\u20134794. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1630","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10130_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","volume":"4","author":"C Glen","year":"2022","unstructured":"Glen, C., Tan, Y. Y., Waterston, A., et al. (2022). Mechanistic and clinical overview cardiovascular toxicity of BRAF and MEK Inhibitors: JACC: CardioOncology state-of-the-art review. JACC CardioOncol, 4(1), 1\u201318. https:\/\/doi.org\/10.1016\/j.jaccao.2022.01.096","journal-title":"JACC CardioOncol"},{"issue":"4","key":"10130_CR52","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S1470-2045(14)70051-8","volume":"15","author":"J Larkin","year":"2014","unstructured":"Larkin, J., Del Vecchio, M., Ascierto, P. A., et al. (2014). Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. The Lancet Oncology, 15(4), 436\u2013444. https:\/\/doi.org\/10.1016\/S1470-2045(14)70051-8","journal-title":"The Lancet Oncology"},{"issue":"26","key":"10130_CR53","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1200\/JCO.2013.49.8691","volume":"31","author":"PA Ascierto","year":"2013","unstructured":"Ascierto, P. A., Minor, D., Ribas, A., et al. (2013). Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. Journal Of Clinical Oncology, 31(26), 3205\u20133211. https:\/\/doi.org\/10.1200\/JCO.2013.49.8691","journal-title":"Journal Of Clinical Oncology"},{"key":"10130_CR54","doi-asserted-by":"publisher","first-page":"956538","DOI":"10.3389\/fcvm.2022.956538","volume":"9","author":"JJA van Bavel","year":"2022","unstructured":"van Bavel, J. J. A., Pham, C., Beekman, H. D. M., et al. (2022). PI3K\/mTOR inhibitor omipalisib prolongs cardiac repolarization along with a mild proarrhythmic outcome in the AV block dog model. Front Cardiovasc Med, 9, 956538. https:\/\/doi.org\/10.3389\/fcvm.2022.956538","journal-title":"Front Cardiovasc Med"},{"issue":"21","key":"10130_CR55","doi-asserted-by":"publisher","first-page":"5573","DOI":"10.1182\/blood.V122.21.5573.5573","volume":"122","author":"F Jin","year":"2013","unstructured":"Jin, F., Robeson, M., Zhou, H., Nichols, A., & Ramanathan, S. (2013). Evaluation Of The Effect Of Idelalisib On The QT\/QTc Interval In Healthy Subjects. Blood, 122(21), 5573. https:\/\/doi.org\/10.1182\/blood.V122.21.5573.5573","journal-title":"Blood"},{"key":"10130_CR56","unstructured":"Summary, M. D. R. (2025). Clinical, Non. Docslib. Accessed September 23. https:\/\/docslib.org\/doc\/8483763\/multi-discipline-review-summary-clinical-non"},{"issue":"6","key":"10130_CR57","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1007\/s00280-012-1845-7","volume":"69","author":"JP Boni","year":"2012","unstructured":"Boni, J. P., Leister, C., Hug, B., Burns, J., & Sonnichsen, D. (2012). A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults. Cancer Chemotherapy And Pharmacology, 69(6), 1433\u20131442. https:\/\/doi.org\/10.1007\/s00280-012-1845-7","journal-title":"Cancer Chemotherapy And Pharmacology"},{"issue":"16","key":"10130_CR58","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.3390\/cancers16162869","volume":"16","author":"JH Kim","year":"2024","unstructured":"Kim, J. H. (2024). Profiling the Cardiovascular Toxicities of CDK4\/6 Inhibitors: A Real-World Pharmacovigilance Study. Cancers, 16(16), 2869. https:\/\/doi.org\/10.3390\/cancers16162869","journal-title":"Cancers"},{"issue":"5","key":"10130_CR59","doi-asserted-by":"publisher","first-page":"pkae078","DOI":"10.1093\/jncics\/pkae078","volume":"8","author":"B Murad","year":"2024","unstructured":"Murad, B., Reis, P. C. A., Deberaldini Marinho, A., et al. (2024). QTc prolongation across CDK4\/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. JNCI Cancer Spectr, 8(5), pkae078. https:\/\/doi.org\/10.1093\/jncics\/pkae078","journal-title":"JNCI Cancer Spectr"},{"key":"10130_CR60","doi-asserted-by":"publisher","first-page":"1558128","DOI":"10.3389\/fphar.2025.1558128","volume":"16","author":"W Liu","year":"2025","unstructured":"Liu, W., Gao, F., Song, X., et al. (2025). Emerging cardiovascular toxicity associated with CDK4\/6 inhibitors: real-world insights from the FDA adverse event reporting system. Frontiers In Pharmacology, 16, 1558128. https:\/\/doi.org\/10.3389\/fphar.2025.1558128","journal-title":"Frontiers In Pharmacology"},{"key":"10130_CR61","unstructured":"Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood | Syndax Pharmaceuticals, Inc. Accessed March 3 (2026). https:\/\/ir.syndax.com\/news-releases\/news-release-details\/syndax-announces-publication-pivotal-revumenib-data-relapsed-or"},{"key":"10130_CR62","unstructured":"Research, C., & for DE (2026). and. FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation. FDA. Published online November 13, 2025. Accessed March 3. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ziftomenib-relapsed-or-refractory-acute-myeloid-leukemia-npm1-mutation"},{"key":"10130_CR63","unstructured":"DailyMed - FARYDAK- panobinostat capsule. Accessed March 3 (2026). https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=1b97bd3a-1040-4511-b0e6-4758e8083ae5"},{"key":"10130_CR64","unstructured":"Secura Bio, I.(2022). ; Withdrawal of Approval of New Drug Application for FARYDAK (Panobinostat) Capsules, 10 Milligrams, 15 Milligrams, and 20 Milligrams. Federal Register. March 24 Accessed March 3, 2026. https:\/\/www.federalregister.gov\/documents\/2022\/03\/24\/2022-06182\/secura-bio-inc-withdrawal-of-approval-of-new-drug-application-for-farydak-panobinostat-capsules-10?utm_source=chatgpt.com"},{"issue":"11","key":"10130_CR65","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1158\/1078-0432.CCR-13-0109","volume":"19","author":"AM Noonan","year":"2013","unstructured":"Noonan, A. M., Eisch, R. A., Liewehr, D. J., et al. (2013). Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel. Clinical Cancer Research, 19(11), 3095\u20133104. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0109","journal-title":"Clinical Cancer Research"},{"issue":"16","key":"10130_CR66","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos, P., Recher, C., Vives, S., et al. (2022). Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. New England Journal Of Medicine, 386(16), 1519\u20131531. https:\/\/doi.org\/10.1056\/NEJMoa2117344","journal-title":"New England Journal Of Medicine"},{"key":"10130_CR67","unstructured":"Agios Announces, F. D. A. (2026). Acceptance of Supplemental New Drug Application for TIBSOVO\u00ae (ivosidenib) for the Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation Not Eligible for Standard Therapy \u2013 Agios Pharmaceuticals, Inc. Accessed March 3. https:\/\/investor.agios.com\/news-releases\/news-release-details\/agios-announces-fda-acceptance-supplemental-new-drug-application"},{"issue":"1","key":"10130_CR68","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1016\/S2352-3026(22)00292-7","volume":"10","author":"JM Watts","year":"2023","unstructured":"Watts, J. M., Baer, M. R., Yang, J., et al. (2023). Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial. Lancet Haematol, 10(1), e46\u2013e58. https:\/\/doi.org\/10.1016\/S2352-3026(22)00292-7","journal-title":"Lancet Haematol"},{"issue":"21","key":"10130_CR69","doi-asserted-by":"publisher","first-page":"4412","DOI":"10.1158\/1078-0432.CCR-25-1333","volume":"31","author":"MI Barbato","year":"2025","unstructured":"Barbato, M. I., Barone, A. K., Aungst, S. L., et al. (2025). FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgery. Clinical Cancer Research, 31(21), 4412\u20134418. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-1333","journal-title":"Clinical Cancer Research"},{"issue":"5","key":"10130_CR70","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1093\/cvr\/cvz026","volume":"115","author":"JR Hu","year":"2019","unstructured":"Hu, J. R., Florido, R., Lipson, E. J., et al. (2019). Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res, 115(5), 854\u2013868. https:\/\/doi.org\/10.1093\/cvr\/cvz026","journal-title":"Cardiovasc Res"},{"issue":"7","key":"10130_CR71","first-page":"473","volume":"42","author":"M Li","year":"2017","unstructured":"Li, M., Ramos, L. G., & Drug-Induced, Q. T. (2017). Prolongation And Torsades de Pointes. P T, 42(7), 473\u2013477.","journal-title":"P T"},{"key":"10130_CR72","doi-asserted-by":"publisher","first-page":"1255825","DOI":"10.3389\/fimmu.2024.1255825","volume":"15","author":"C Zhang","year":"2024","unstructured":"Zhang, C., Wei, F., Ma, W., & Zhang, J. (2024). Immune-related cardiovascular toxicities of PD-1\/PD-L1 inhibitors in solid tumors: an updated systematic review and meta-analysis. Frontiers In Immunology, 15, 1255825. https:\/\/doi.org\/10.3389\/fimmu.2024.1255825","journal-title":"Frontiers In Immunology"},{"key":"10130_CR73","doi-asserted-by":"publisher","first-page":"11456","DOI":"10.3389\/or.2023.11456","volume":"17","author":"RK Paluri","year":"2023","unstructured":"Paluri, R. K., Pulipati, Y., & Regalla, D. K. R. (2023). Immune Checkpoint Inhibitors and Their Cardiovascular Adverse Effects. Oncol Rev, 17, 11456. https:\/\/doi.org\/10.3389\/or.2023.11456","journal-title":"Oncol Rev"},{"issue":"1","key":"10130_CR74","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13046-021-02148-6","volume":"40","author":"X Xiao","year":"2021","unstructured":"Xiao, X., Huang, S., Chen, S., et al. (2021). Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. Journal Of Experimental & Clinical Cancer Research : Cr, 40(1), 367. https:\/\/doi.org\/10.1186\/s13046-021-02148-6","journal-title":"Journal Of Experimental & Clinical Cancer Research : Cr"},{"issue":"2","key":"10130_CR75","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s11912-024-01634-2","volume":"27","author":"T Joseph","year":"2025","unstructured":"Joseph, T., Sanchez, J., Abbasi, A., Zhang, L., Sica, R. A., & Duong, T. Q. (2025). Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review. Current Oncology Reports, 27(2), 135\u2013147. https:\/\/doi.org\/10.1007\/s11912-024-01634-2","journal-title":"Current Oncology Reports"},{"key":"10130_CR76","unstructured":"Research, C. for, DE, E., & Clinical, S. B. (2022). and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential\u2013Questions and Answers. August 26, Accessed October 5, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e14-and-s7b-clinical-and-nonclinical-evaluation-qtqtc-interval-prolongation-and-proarrhythmic"},{"issue":"3","key":"10130_CR77","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/bcp.13832","volume":"85","author":"JE Hibma","year":"2019","unstructured":"Hibma, J. E., Kantarjian, H. M., DeAngelo, D. J., & Boni, J. P. (2019). Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc-concentration modelling. British journal of clinical pharmacology, 85(3), 590\u2013600. https:\/\/doi.org\/10.1111\/bcp.13832","journal-title":"British journal of clinical pharmacology"},{"issue":"1","key":"10130_CR78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00280-015-2776-x","volume":"76","author":"JM van der Burke","year":"2015","unstructured":"van der Burke, J. M., Flinn, I. W., et al. (2015). Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma. Cancer Chemotherapy And Pharmacology, 76(1), 211\u2013216. https:\/\/doi.org\/10.1007\/s00280-015-2776-x","journal-title":"Cancer Chemotherapy And Pharmacology"},{"issue":"39\u201340","key":"10130_CR79","doi-asserted-by":"publisher","first-page":"556","DOI":"10.4414\/smw.2007.11899","volume":"137","author":"O Yavas","year":"2007","unstructured":"Yavas, O., Yazici, M., Eren, O., & Oyan, B. (2007). The acute effect of trastuzumab infusion on ECG parameters in metastatic breast cancer patients. Swiss Medical Weekly, 137(39\u201340), 556\u2013558. https:\/\/doi.org\/10.4414\/smw.2007.11899","journal-title":"Swiss Medical Weekly"},{"issue":"11","key":"10130_CR80","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.3390\/nu12113277","volume":"12","author":"G Pietropaolo","year":"2020","unstructured":"Pietropaolo, G., Pugliese, D., Armuzzi, A., et al. (2020). Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy. Nutrients, 12(11), 3277. https:\/\/doi.org\/10.3390\/nu12113277","journal-title":"Nutrients"},{"key":"10130_CR81","unstructured":"DailyMed - PORTRAZZA- necitumumab solution. Accessed March 4 (2026). https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=89bcf553-669a-40b0-a9d7-67a5c1d2f591"},{"key":"10130_CR82","unstructured":"DailyMed - ERBITUX- cetuximab solution. Accessed March 4 (2026). https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=8bc6397e-4bd8-4d37-a007-a327e4da34d9"},{"key":"10130_CR83","unstructured":"Toremifene (2026). Dosage, Mechanism\/Onset of Action, Half-Life. Medicine.com. Accessed March 4. http:\/\/www.medicine.com\/drug\/toremifene\/hcp"},{"issue":"7","key":"10130_CR84","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1177\/1078155217720006","volume":"24","author":"K Fung","year":"2018","unstructured":"Fung, K., Imeson, J., & Cusano, F. (2018). The clinical significance of QT prolongation associated with tamoxifen: A review of the literature. Journal Of Oncology Pharmacy Practice : Official Publication Of The International Society Of Oncology Pharmacy Practitioners, 24(7), 525\u2013530. https:\/\/doi.org\/10.1177\/1078155217720006","journal-title":"Journal Of Oncology Pharmacy Practice : Official Publication Of The International Society Of Oncology Pharmacy Practitioners"},{"issue":"9","key":"10130_CR85","doi-asserted-by":"publisher","first-page":"100882","DOI":"10.1016\/j.cpcardiol.2021.100882","volume":"47","author":"G Gutierrez","year":"2022","unstructured":"Gutierrez, G., Wamboldt, R., & Baranchuk, A. (2022). The Impact of Testosterone on the QT Interval: A Systematic Review. Current Problems In Cardiology, 47(9), 100882. https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100882","journal-title":"Current Problems In Cardiology"},{"issue":"23","key":"10130_CR86","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","volume":"382","author":"ND Shore","year":"2020","unstructured":"Shore, N. D., Saad, F., Cookson, M. S., et al. (2020). Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. New England Journal Of Medicine, 382(23), 2187\u20132196. https:\/\/doi.org\/10.1056\/NEJMoa2004325","journal-title":"New England Journal Of Medicine"},{"key":"10130_CR87","doi-asserted-by":"publisher","first-page":"613625","DOI":"10.3389\/fcvm.2021.613625","volume":"8","author":"P Kim","year":"2021","unstructured":"Kim, P., Masha, L., Olson, A., et al. (2021). QT Prolongation in Cancer Patients. Front Cardiovasc Med, 8, 613625. https:\/\/doi.org\/10.3389\/fcvm.2021.613625","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10130_CR88","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s40360-017-0181-2","volume":"18","author":"Q Khan","year":"2017","unstructured":"Khan, Q., Ismail, M., & Khan, S. (2017). Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. BMC Pharmacol Toxicol, 18(1), 75. https:\/\/doi.org\/10.1186\/s40360-017-0181-2","journal-title":"BMC Pharmacol Toxicol"},{"issue":"3","key":"10130_CR89","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1128\/AAC.00958-12","volume":"57","author":"JD Zeuli","year":"2013","unstructured":"Zeuli, J. D., Wilson, J. W., & Estes, L. L. (2013). Effect of combined fluoroquinolone and azole use on QT prolongation in hematology patients. Antimicrobial Agents And Chemotherapy, 57(3), 1121\u20131127. https:\/\/doi.org\/10.1128\/AAC.00958-12","journal-title":"Antimicrobial Agents And Chemotherapy"},{"issue":"4","key":"10130_CR90","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/s0009-9236(03)00009-2","volume":"73","author":"GJ Noel","year":"2003","unstructured":"Noel, G. J., Natarajan, J., Chien, S., Hunt, T. L., Goodman, D. B., & Abels, R. (2003). Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clinical Pharmacology And Therapeutics, 73(4), 292\u2013303. https:\/\/doi.org\/10.1016\/s0009-9236(03)00009-2","journal-title":"Clinical Pharmacology And Therapeutics"},{"issue":"1","key":"10130_CR91","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12941-019-0311-3","volume":"18","author":"ET Van Matre","year":"2019","unstructured":"Van Matre, E. T., Evans, S. L., Mueller, S. W., MacLaren, R., Fish, D. N., & Kiser, T. H. (2019). Comparative evaluation of isavuconazonium sulfate, voriconazole, and posaconazole for the management of invasive fungal infections in an academic medical center. Annals Of Clinical Microbiology And Antimicrobials, 18(1), 13. https:\/\/doi.org\/10.1186\/s12941-019-0311-3","journal-title":"Annals Of Clinical Microbiology And Antimicrobials"},{"issue":"9","key":"10130_CR92","doi-asserted-by":"publisher","first-page":"e0017722","DOI":"10.1128\/aac.00177-22","volume":"66","author":"JS Lewis","year":"2022","unstructured":"Lewis, J. S., Wiederhold, N. P., Hakki, M., & Thompson, G. R. (2022). New Perspectives on Antimicrobial Agents: Isavuconazole. Antimicrobial Agents And Chemotherapy, 66(9), e0017722. https:\/\/doi.org\/10.1128\/aac.00177-22","journal-title":"Antimicrobial Agents And Chemotherapy"},{"key":"10130_CR93","unstructured":"Prevention of chemotherapy-induced nausea and vomiting in adults - UpToDate. Accessed September 24, (2025). https:\/\/www.uptodate.com\/contents\/prevention-of-chemotherapy-induced-nausea-and-vomiting-in-adults?topicRef=2538&source=see_link"},{"issue":"2","key":"10130_CR94","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00520-015-2822-6","volume":"24","author":"J Morganroth","year":"2016","unstructured":"Morganroth, J., Flaharty, K. K., Parisi, S., & Moresino, C. (2016). Effect of single doses of IV palonosetron, up to 2.25\u00a0mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. Supportive Care In Cancer, 24(2), 621\u2013627. https:\/\/doi.org\/10.1007\/s00520-015-2822-6","journal-title":"Supportive Care In Cancer"},{"issue":"2","key":"10130_CR95","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1213\/ane.0b013e3181ac1066","volume":"109","author":"TC Marbury","year":"2009","unstructured":"Marbury, T. C., Jin, B., Panebianco, D., et al. (2009). Lack of effect of aprepitant or its prodrug fosaprepitant on QTc intervals in healthy subjects. Anesthesia And Analgesia, 109(2), 418\u2013425. https:\/\/doi.org\/10.1213\/ane.0b013e3181ac1066","journal-title":"Anesthesia And Analgesia"},{"key":"10130_CR96","doi-asserted-by":"publisher","first-page":"1363848","DOI":"10.3389\/fcvm.2024.1363848","volume":"11","author":"Y Tsuji","year":"2024","unstructured":"Tsuji, Y., Yamazaki, M., Shimojo, M., Yanagisawa, S., Inden, Y., & Murohara, T. (2024). Mechanisms of torsades de pointes: an update. Front Cardiovasc Med, 11, 1363848. https:\/\/doi.org\/10.3389\/fcvm.2024.1363848","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10130_CR97","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/jce.15832","volume":"34","author":"B Belhassen","year":"2023","unstructured":"Belhassen, B., & Tovia-Brodie, O. (2023). Short or long-coupled idiopathic ventricular fibrillation: Does the coupling interval really matter? Journal of Cardiovascular Electrophysiology, 34(3), 624\u2013626. https:\/\/doi.org\/10.1111\/jce.15832","journal-title":"Journal of Cardiovascular Electrophysiology"},{"issue":"8","key":"10130_CR98","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","volume":"121","author":"BJ Drew","year":"2010","unstructured":"Drew, B. J., Ackerman, M. J., Funk, M., et al. (2010). Prevention of torsade de pointes in hospital settings: A scientific statement from the American heart association and the American college of cardiology foundation. Circulation, 121(8), 1047\u20131060. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.192704","journal-title":"Circulation"},{"issue":"3","key":"10130_CR99","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1161\/01.cir.84.3.1136","volume":"84","author":"AJ Moss","year":"1991","unstructured":"Moss, A. J., Schwartz, P. J., Crampton, R. S., et al. (1991). The long QT syndrome: Prospective longitudinal study of 328 families. Circulation, 84(3), 1136\u20131144. https:\/\/doi.org\/10.1161\/01.cir.84.3.1136","journal-title":"Circulation"},{"issue":"39","key":"10130_CR100","doi-asserted-by":"publisher","first-page":"25738","DOI":"10.18632\/oncotarget.25008","volume":"9","author":"J Duan","year":"2018","unstructured":"Duan, J., Tao, J., Zhai, M., et al. (2018). Anticancer drugs-related QTc prolongation, torsade de pointes and sudden death: Current evidence and future research perspectives. Oncotarget, 9(39), 25738\u201325749. https:\/\/doi.org\/10.18632\/oncotarget.25008","journal-title":"Oncotarget"},{"issue":"4","key":"10130_CR101","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/j.1542-474X.2008.00254.x","volume":"13","author":"EDV Garcia","year":"2008","unstructured":"Garcia, E. D. V. (2008). T-wave alternans: Reviewing the clinical performance, understanding limitations, characterizing methodologies. Annals of Noninvasive Electrocardiology, 13(4), 401\u2013420. https:\/\/doi.org\/10.1111\/j.1542-474X.2008.00254.x","journal-title":"Annals of Noninvasive Electrocardiology"},{"issue":"3","key":"10130_CR102","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.1161\/CIR.0000000000000986","volume":"144","author":"MG Fradley","year":"2021","unstructured":"Fradley, M. G., Beckie, T. M., Brown, S. A., et al. (2021). Recognition, Prevention, and Management of Arrhythmias and Autonomic Disorders in Cardio-Oncology: A Scientific Statement from the American Heart Association. Circulation, 144(3), E41\u2013E55. https:\/\/doi.org\/10.1161\/CIR.0000000000000986","journal-title":"Circulation"},{"issue":"Fig. 1","key":"10130_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/9870283","volume":"2019","author":"V Zeitjian","year":"2019","unstructured":"Zeitjian, V., Moazez, C., Arslan, W., & Saririan, M. (2019). QT Independent Ventricular Tachycardia Induced by Arsenic Trioxide. Case Reports in Cardiology, 2019(Fig. 1), 1\u20133. https:\/\/doi.org\/10.1155\/2019\/9870283","journal-title":"Case Reports in Cardiology"},{"issue":"2","key":"10130_CR104","doi-asserted-by":"publisher","first-page":"e000701","DOI":"10.1136\/openhrt-2017-000701","volume":"4","author":"MG Fradley","year":"2017","unstructured":"Fradley, M. G., Viganego, F., Kip, K., et al. (2017). Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies. Open Heart, 4(2), e000701. https:\/\/doi.org\/10.1136\/openhrt-2017-000701","journal-title":"Open Heart"},{"issue":"5","key":"10130_CR105","doi-asserted-by":"publisher","first-page":"S431","DOI":"10.1016\/j.hrthm.2022.03.1025","volume":"19","author":"S Sherazi","year":"2022","unstructured":"Sherazi, S., Patel, A., Hsu, K., et al. (2022). Po-699-07 Risk of Sudden Cardiac Death in Patients Undergoing Cancer Treatment. Heart Rhythm : The Official Journal Of The Heart Rhythm Society, 19(5), S431\u2013S432. https:\/\/doi.org\/10.1016\/j.hrthm.2022.03.1025","journal-title":"Heart Rhythm : The Official Journal Of The Heart Rhythm Society"},{"issue":"Supplement_2","key":"10130_CR106","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1093\/ehjci\/ehaa946.3565","volume":"41","author":"M Mirabel","year":"2020","unstructured":"Mirabel, M., Hulot, J. S., Lillo-Lelouet, A., Jouven, X., & Marijon, E. (2020). Sudden cardiac death in cancer patients: results from the Paris-Sudden Death Expertise Centre. European Heart Journal, 41(Supplement_2), 3565. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.3565","journal-title":"European Heart Journal"},{"key":"10130_CR107","doi-asserted-by":"publisher","unstructured":"Keramida, K., Kariki, O., Angelopoulou, E., et al. (2025). Arrhythmias, conduction disorders and sudden cardiac death in cancer patients and survivors: expert opinion of the working groups on cardio-oncology and on electrophysiology of the hellenic cardiac society. Cardio-Oncology, 11(1). https:\/\/doi.org\/10.1186\/s40959-025-00363-0","DOI":"10.1186\/s40959-025-00363-0"},{"key":"10130_CR108","doi-asserted-by":"publisher","unstructured":"Acute promyelocytic leukemia?, G. H. I. T. I. S. J. (1963). Blood. ;21(26):237\u2013240. doi:https:\/\/doi.org\/10.1182\/blood.v21.2.237.237.","DOI":"10.1182\/blood.v21.2.237.237"},{"issue":"5","key":"10130_CR109","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/070674371506000502","volume":"60","author":"SW Rabkin","year":"2015","unstructured":"Rabkin, S. W. (2015). Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics. Canadian Journal Of Psychiatry, 60(5), 206\u2013214. https:\/\/doi.org\/10.1177\/070674371506000502","journal-title":"Canadian Journal Of Psychiatry"},{"issue":"9","key":"10130_CR110","doi-asserted-by":"publisher","first-page":"740","DOI":"10.11909\/j.issn.1671-5411.2016.09.013","volume":"13","author":"SW Rabkin","year":"2016","unstructured":"Rabkin, S. W., Cheng, X. B. J., & Thompson, D. J. (2016). Detailed analysis of the impact of age on the QT interval. J Geriatr Cardiol, 13(9), 740\u2013748. https:\/\/doi.org\/10.11909\/j.issn.1671-5411.2016.09.013","journal-title":"J Geriatr Cardiol"},{"issue":"9","key":"10130_CR111","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1001\/archinte.164.9.943","volume":"164","author":"A Montanez","year":"2004","unstructured":"Montanez, A., Ruskin, J. N., Hebert, P. R., Lamas, G. A., & Hennekens, C. H. (2004). Prolonged QTc interval and risks of total and cardiovascular mortality and sudden death in the general population: a review and qualitative overview of the prospective cohort studies. Archives Of Internal Medicine, 164(9), 943\u2013948. https:\/\/doi.org\/10.1001\/archinte.164.9.943","journal-title":"Archives Of Internal Medicine"},{"issue":"11","key":"10130_CR112","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1093\/annonc\/mds130","volume":"23","author":"A Naing","year":"2012","unstructured":"Naing, A., Veasey-Rodrigues, H., Hong, D. S., et al. (2012). Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs. Annals Of Oncology, 23(11), 2960\u20132963. https:\/\/doi.org\/10.1093\/annonc\/mds130","journal-title":"Annals Of Oncology"},{"issue":"4","key":"10130_CR113","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCOUTCOMES.113.000152","volume":"6","author":"JE Tisdale","year":"2013","unstructured":"Tisdale, J. E., Jaynes, H. A., Kingery, J. R., et al. (2013). Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circulation. Cardiovascular Quality And Outcomes, 6(4), 479\u2013487. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.113.000152","journal-title":"Circulation. Cardiovascular Quality And Outcomes"},{"issue":"2","key":"10130_CR114","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1007\/s11096-017-0446-2","volume":"39","author":"E Vandael","year":"2017","unstructured":"Vandael, E., Vandenberk, B., Vandenberghe, J., Spriet, I., Willems, R., & Foulon, V. (2017). Development of a risk score for QTc-prolongation: the RISQ-PATH study. Int J Clin Pharm, 39(2), 424\u2013432. https:\/\/doi.org\/10.1007\/s11096-017-0446-2","journal-title":"Int J Clin Pharm"},{"issue":"12","key":"10130_CR115","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1111\/bcp.13740","volume":"84","author":"E Vandael","year":"2018","unstructured":"Vandael, E., Vandenberk, B., Van den Vandenberghe, J., Willems, R., & Foulon, V. (2018). A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model. British Journal Of Clinical Pharmacology, 84(12), 2824\u20132835. https:\/\/doi.org\/10.1111\/bcp.13740","journal-title":"British Journal Of Clinical Pharmacology"},{"issue":"2","key":"10130_CR116","doi-asserted-by":"publisher","first-page":"e001488","DOI":"10.1136\/bmjoq-2021-001488","volume":"10","author":"I Trip","year":"2021","unstructured":"Trip, I., George, S., Thomson, M., Petty, R. D., & Baxter, M. A. (2021). Cancer Treatment Helpline: a retrospective study of the NHS Tayside experience. BMJ Open Qual, 10(2), e001488. https:\/\/doi.org\/10.1136\/bmjoq-2021-001488","journal-title":"BMJ Open Qual"},{"issue":"10","key":"10130_CR117","doi-asserted-by":"publisher","first-page":"e241","DOI":"10.1161\/CIRCULATIONAHA.108.191096","volume":"119","author":"PM Rautaharju","year":"2009","unstructured":"Rautaharju, P. M., Surawicz, B., Gettes, L. S., et al. (2009). AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation, 119(10), e241\u2013250. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.191096","journal-title":"Circulation"},{"key":"10130_CR118","doi-asserted-by":"publisher","first-page":"100636","DOI":"10.1016\/j.ijcha.2020.100636","volume":"30","author":"H Bogossian","year":"2020","unstructured":"Bogossian, H., Linz, D., Heijman, J., et al. (2020). QTc evaluation in patients with bundle branch block. Int J Cardiol Heart Vasc, 30, 100636. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100636","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"11","key":"10130_CR119","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1046\/j.1460-9592.2002.01612.x","volume":"25","author":"SL Pinski","year":"2002","unstructured":"Pinski, S. L., Egu\u00eda, L. E., & Trohman, R. G. (2002). What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers. Pacing And Clinical Electrophysiology, 25(11), 1612\u20131615. https:\/\/doi.org\/10.1046\/j.1460-9592.2002.01612.x","journal-title":"Pacing And Clinical Electrophysiology"},{"issue":"11","key":"10130_CR120","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/nrd2423","volume":"6","author":"RA Wilke","year":"2007","unstructured":"Wilke, R. A., Lin, D. W., Roden, D. M., et al. (2007). Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nature Reviews. Drug Discovery, 6(11), 904\u2013916. https:\/\/doi.org\/10.1038\/nrd2423","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"4","key":"10130_CR121","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1124\/pr.110.003723","volume":"62","author":"P Kannankeril","year":"2010","unstructured":"Kannankeril, P., Roden, D. M., & Darbar, D. (2010). Drug-induced long QT syndrome. Pharmacological Reviews, 62(4), 760\u2013781. https:\/\/doi.org\/10.1124\/pr.110.003723","journal-title":"Pharmacological Reviews"},{"issue":"1","key":"10130_CR122","doi-asserted-by":"publisher","first-page":"e22296","DOI":"10.2196\/22296","volume":"5","author":"A Chandra","year":"2021","unstructured":"Chandra, A., Philips, S. T., Pandey, A., et al. (2021). Electronic Health Records-Based Cardio-Oncology Registry for Care Gap Identification and Pragmatic Research: Procedure and Observational Study. JMIR Cardio, 5(1), e22296. https:\/\/doi.org\/10.2196\/22296","journal-title":"JMIR Cardio"},{"issue":"6","key":"10130_CR123","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/diagnostics15060787","volume":"15","author":"LC Nechita","year":"2025","unstructured":"Nechita, L. C., Tutunaru, D., Nechita, A., et al. (2025). AI and Smart Devices in Cardio-Oncology: Advancements in Cardiotoxicity Prediction and Cardiovascular Monitoring. Diagnostics (Basel), 15(6), 787. https:\/\/doi.org\/10.3390\/diagnostics15060787","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"10130_CR124","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.3390\/s21072539","volume":"21","author":"D Duncker","year":"2021","unstructured":"Duncker, D., Ding, W. Y., Etheridge, S., et al. (2021). Smart Wearables for Cardiac Monitoring-Real-World Use beyond Atrial Fibrillation. Sensors (Basel), 21(7), 2539. https:\/\/doi.org\/10.3390\/s21072539","journal-title":"Sensors (Basel)"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10130-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10130-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:20:28Z","timestamp":1782847228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10130-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,23]]},"references-count":124,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10130"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10130-x","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,23]]},"assertion":[{"value":"5 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"58"}}